TransMedics reports record Q3 2026 revenue and lifts full-year guidance
TransMedics Group posted third‑quarter 2026 revenue of $203.0 million, a 41% year‑over‑year increase, and net income of $17.1 million. The company raised its full‑year 2026 revenue outlook to $764 million‑$774 million, including about $14 million from its PAD Aviation investment. It also announced FDA IDE approvals for the ENHANCE Heart Part B and DENOVO Lung trials and secured its first European transplant‑logistics tender in Italy. A new CFO, Fernando Araujo, was appointed.
Why it matters
The higher revenue guidance expands the upside potential for investors, as noted by Canaccord’s upgraded price target to $120. The FDA approvals and European tender signal continued pipeline and market expansion, supporting the guidance raise.
Key facts
- 1Q3 2026 revenue was $203.0 million, up 41% YoY prnewswire.com
- 2Net income for the quarter was $17.1 million prnewswire.com
- 3Full‑year 2026 revenue guidance was increased to $764 million‑$774 million, inclusive of approximately $14 million from PAD Aviation prnewswire.com
- 4Received FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung trials prnewswire.com
- 5Awarded its first European transplant‑logistics tender in Italy prnewswire.com
- 6Appointed Fernando Araujo as Chief Financial Officer prnewswire.com
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.